PRQR News and Press, ProQR Therapeutics N.V. From 08/11/22

Dutch biotech ProQR Therapeutics N.V. ( NASDAQ: PRQR ) announced on Thursday that the European Medicines Agency (EMA) recommended an additional pivotal clinical trial before submitting a marketing application for the company’s lead candidate sepofarsen. An investiga...

In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer ® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023 Additional pivotal trial reco...

ProQR press release ( NASDAQ: PRQR ): Q2 GAAP EPS of -€0.21 beats by €0.02 . Revenue of €1.02M (+325.0% Y/Y) beats by €0.07M . For further details see: ProQR GAAP EPS of -$0.21 beats by €0.02, revenue of €1.0...

ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022 Company plans to discuss findings from sepofarsen Illuminate trial with regulators and prov...

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced that Company management will partic...

Annual General Meeting of Shareholders to be held on June 30, 2022 René Beukema joins management team as Chief Corporate Development Officer and General Counsel and is nominated to Management Board Gerard Platenburg to assume Chief Scientific Officer role, with leadership ove...

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotid...

ProQR press release (NASDAQ:PRQR): Q1 GAAP EPS of -€0.20. Revenue of €1.23M. For further details see: ProQR GAAP EPS of -€0.20, revenue of €1.23M

Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and provide an ...

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced several presentations at the 7th A...